ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CRX Cyprotex

160.50
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cyprotex LSE:CRX London Ordinary Share GB00BP25RZ14 ORD £0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 160.50 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Cyprotex PLC Director Dealing (4645A)

22/12/2014 12:12pm

UK Regulatory


Cyprotex (LSE:CRX)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Cyprotex Charts.

TIDMCRX

RNS Number : 4645A

Cyprotex PLC

22 December 2014

Cyprotex PLC

("Cyprotex" or "the Company")

Director dealing

The Company received notification that Ralph Stephen Harris, Non-executive Director of the Company, acquired 25,000 ordinary shares in the Company on 19 December 2014 at a price of 42.5 pence per share. As a result of this purchase Mr. Harris has a beneficial interest in 235,514 ordinary shares in the Company representing approximately 1.05 per cent. of the Company's total voting rights.

 
 
 
 
 
   Cyprotex PLC 
                                           Tel : +44 (0)1625 
                                           505 100 
 Dr Anthony Baxter, Chief Executive 
  Officer 
 John Dootson, Chief Financial Officer 
 Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 ir@cyprotex.com                         www.cyprotex.com 
 
 N + 1 Singer (NOMAD and broker to       Tel : +44 (0)20 
  Cyprotex)                               7496 3000 
 Shaun Dobson 
 shaun.dobson@n1singer.com 
 Jen Boorer 
 jen.boorer@n1singer.com                 www.nplus1singer.com 
 
 

About Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites in Macclesfield, near Manchester in the UK, Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1,000 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSPGGMUPUPCGPP

1 Year Cyprotex Chart

1 Year Cyprotex Chart

1 Month Cyprotex Chart

1 Month Cyprotex Chart

Your Recent History

Delayed Upgrade Clock